Amgen Inc (AMGN) Stock AnalysisAMGNStock AnalysisAmgen Inc

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Amgen Inc is a good buy right now due to its strong financial performance and positive catalysts. The current price of $432.42 is close to the Fibonacci Pivot level of $431.007, which suggests a potential support level. Additionally, the forward P/E ratio of 19.6464 indicates that the stock is reasonably valued compared to its earnings potential. The recent positive clinical trial results for Tezspire in eosinophilic esophagitis could significantly enhance revenue streams, as the drug is already approved for severe asthma in over 70 countries. However, the main risk is the high debt-to-equity ratio of 490.28%, which indicates potential financial leverage concerns.

25 analysts cover AMGN: 10 rate it Buy, 15 Hold and 0 Sell. The average price target is 363.10.